Basic information Diuretics Uses Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Circulatory system drugs >  Antihypertensive drugs >  Torasemide

Torasemide

Basic information Diuretics Uses Safety Supplier Related

Torasemide Basic information

Product Name:
Torasemide
Synonyms:
  • TorseMide(DeMadex)
  • TorseMide API
  • N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide Torasemide
  • TroseMide
  • Torasemide Tables
  • N-[(isopropylamino)carbonyl]-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide
  • DEMADEX
  • JDL-464
CAS:
56211-40-6
MF:
C16H20N4O3S
MW:
348.42
EINECS:
637-197-3
Product Categories:
  • ANTIZOL
  • Inhibitors
  • Active Pharmaceutical Ingredients
  • Diuretic
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • APIs
  • Torasemide
  • All Inhibitors
  • Ion transporter and other ion channel
Mol File:
56211-40-6.mol
More
Less

Torasemide Chemical Properties

Melting point:
163-164°C
Density 
1.283±0.06 g/cm3(Predicted)
storage temp. 
Keep in dark place,Inert atmosphere,Room temperature
solubility 
DMSO: soluble18mg/mL
pka
6.44(at 25℃)
form 
solid
color 
White
Water Solubility 
Soluble
Merck 
14,9552
InChIKey
NGBFQHCMQULJNZ-UHFFFAOYSA-N
CAS DataBase Reference
56211-40-6(CAS DataBase Reference)
EPA Substance Registry System
3-Pyridinesulfonamide, N-[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]- (56211-40-6)
More
Less

Safety Information

Hazard Codes 
Xi
Risk Statements 
36-36/37/38
Safety Statements 
26-37/39
WGK Germany 
2
RTECS 
UT7938000
HS Code 
2935904000

MSDS

More
Less

Torasemide Usage And Synthesis

Diuretics

Diuretics are drugs mainly acting on the kidneys to increase the excretion of water and electrolytes, and increase urine output. Their potency can be divided into:
1. potent diuretics (loop diuretics): including furosemide, bumetanide, ethacrynic acid.
2. Middle efficiency diuretics include: thiazide diuretics, such as hydrochlorothiazide, bendroflumethiazide and so on.
3. Inefficient diuretics include: retention of potassium diuretics spironolactone, triamterene and carbonic anhydrase inhibitor acetazolamide and the like.
Potent diuretics effect on medullary loop ramus crude segment medulla,they inhibit reabsorption of active chlorine, followed by inhibiting sodium reabsorption, and play a strong diuretic effect.
Torasemide is a potent diuretic, its mechanism of action is similar to furosemide, it has no effect on the proximal tubules, it does not cause an increase in the discharge of potassium. This product increase renal volume and sodium excretion is dose-dependent , it does not affect the calcium and potassium excretion, excretion and metabolism have no association with renal function, large doses have no significant toxicity. Sort diuretic strength by: bumetanide> torasemide> piretanide> furosemide. It is useful in the treatment of acute and chronic renal failure and essential hypertension. Adverse reactions of torasemide are similar to furosemide ,common adverse reactions are headache, dizziness, weakness, nausea, muscle spasms, but it produces lesser extent of potassium loss ,it has no effect on uric acid, blood glucose and lipid .
The above information is edited by the chemicalbook of Tian Ye.

Uses

It is used as a diuretic.

Description

Torasemide (Item No. 21312) is an analytical reference standard categorized as a diuretic. Diuretics, including torasemide, have been abused as performance-enhancing drugs and masking agents in doping in sports. This product is intended for research and forensic applications.

Description

Torasemide is a novel loop diuretic launched in 1993 after a 12-year gap from the last diuretic introduction. It is indicated for the treatment of hypertension and edema associated with chronic congestive heart failure, renal disease and hepatic cirrhosis. Torasemide exerts its major diuretic activity on the thick ascending limb of the Henle's loop to promote rapid and marked excretion of water, Na+, Cl-, and to a lesser extent,K+ and Ca2+. Compared with other loop diuretics such as furosemide, torasemide has a stronger antihypertensive action, a higher bioavailability, a longer duration of action that is independent of the renal function, and has no side effects such as paradoxical antidiuresis. The mechanism of its vasodilating effect has been suggested to result from, at least in part, the competitive antagonism of the thromboxane A2 receptor.

Chemical Properties

Crystalline Solid

Originator

Hafslund Nycomed Germany; Italy (Norway)

Uses

alcohol dehydrogenase inhibitor, antidote

Uses

Used as a diuretic.

Uses

Used as a diuretic

Definition

ChEBI: An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea.

Manufacturing Process

In a 100 ml three-necked flask equipped with magnetic stirrer, condenser, thermometer and dropping funnel 3-sulfonylchloride-4-chloropyridine (10 g, 1 eq., 46.7 mmoles) was suspended in t-butyl-methyl ether (MTBE) (30 ml) at room temperature. Ammonium hydroxide, 25% solution (13.5 ml, 2.13 eq.) was dropped into the suspension in a rate such that the temperature is allowed to increase to 22°-26°C, this temperature was maintained until all the ammonium hydroxide was added. The suspension was then to cooled to room temperature and was stirred for 1 h. The pH of the suspension was adjusted to 80.1 by the addition of a few drops of ammonium hydroxide, 25% solution. The suspension was filtered and washed with water (2 times 10 ml) and the wet product (8 g) dried at 40°C, under the 1 mm Hg vacuum. 3-Sulfonamide- 4-chloropyridine was isolated in 74.4% yield, 6.7 g.
A mixture of 0.01 moles of 3-sulfonamido-4-chloropyridine, 0.02 mole of 3- methylbenzylamine and 50 ml of dry ethanol was heated to reflux temperature for 9 h. After distillation of the ethanol the residue was taken up in an excess of diluted NaOH and the excess of amine was extracted by means of ether.
The aqueous solution was then decolourized with charcoal and filtered, and the filtrate was neutralized with acetic acid. The precipitated product was separated and purified by crystallization from a mixture of water and acetone.The 3-sulfonamido-4-(3-methylbenzyl)amino-pyridine crystallized in the form of beige coloured cristals having a melting point of 184°-186°C. 0.01 mole of 3-sulfonamido-4-(3-methylbenzyl)amino-pyridine was reacted with 0.015 mole of isopropylisocyanate in the presence of 0.02 mole of triethylamine and of 20 ml of dichloromethane, at room temperature for 20 h. After evaporation under vacuum, the residue was taken up in an excess of diluted Na2CO3, filtered off and acidified by means of acetic acid. After precipitation of the product it was filtered and washed several times with ice cold water. The 3-isopropylcarbamoylsulfonamido-4-(3-methylbenzyl)amino_x0002_pyridine (Torsemide) showing as a white powder, has a melting point of 147°- 149°C.

brand name

Torasemide is INN and BAN;Unat;Toradiur.

Therapeutic Function

Diuretic

Biochem/physiol Actions

Torsemide is a loop diuretic of the pyridine-sulfonylurea class with antialdosteronergic properties and inhibitor of the Na+/K+/2Cl- carrier system.

Clinical Use

Loop diuretic:
Hypertension
Oedema

Drug interactions

Potentially hazardous interactions with other drugs
Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect with NSAIDs.
Anti-arrhythmics: risk of cardiac toxicity with anti-arrhythmics if hypokalaemia occurs; effects of lidocaine and mexiletine antagonised.
Antibacterials: increased risk of ototoxicity with aminoglycosides, polymyxins and vancomycin; avoid concomitant use with lymecycline.
Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
Antiepileptics: increased risk of hyponatraemia with carbamazepine.
Antifungals: increased risk of hypokalaemia with amphotericin.
Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect with alpha-blockers; increased risk of ventricular arrhythmias with sotalol if hypokalaemia occurs.
Antipsychotics: increased risk of ventricular arrhythmias with amisulpride or pimozide (avoid with pimozide) if hypokalaemia occurs; enhanced hypotensive effect with phenothiazines.
Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias.
Cardiac glycosides: increased toxicity if hypokalaemia occurs.
Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
Lithium: risk of toxicity.

Metabolism

Torasemide is metabolised by the cytochrome P450 isoenzyme CYP2C9 to three inactive metabolites, M1, M3 and M5 by stepwise oxidation, hydroxylation or ring hydroxylation. The inactive metabolites are excreted in the urine.

TorasemideSupplier

Hubei Yuanmeng Biotechnology Co., Ltd Gold
Tel
027-68897569 18120462897
Email
fiona@yuanmengbio.com
Jiangxi ravel Biotechnology Co.,Ltd Gold
Tel
400-880-2824 15608648206
Email
1987516016@qq.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
18621169121
Email
market03@meryer.com